 |
 |
||
 |
Boost your skills by attending one of PharmaVentures' popular workshops: Advanced Valuation of Pharmaceutical Strategic Alliances25-26 October In this intensive two-day Advanced Workshop in Princeton, USA, PharmaVentures will share its insights into cutting-edge approaches, methods and techniques for the valuation of pharmaceutical products, technologies, alliances and ventures. Find out more Negotiating Successful Strategic Alliances & Calculating their Financial Terms11-13 December If you're involved in negotiating multi-million dollar licensing agreements, you'll want to get the very best out of every deal. This workshop provides a coaching opportunity for experienced negotiators as well as comprehensive training towards further involvement in the negotiation process. |
||
 |
 |
||
 |
Market News and TrendsDuring September 2006, PharmaDeals® Agreements recorded a total of 11 deals relating to drug delivery, continuing the year's irregular pattern. This was ten less than the number of drug delivery deals recorded for August. Unusually, only one of the 11 agreements featured two start-up and emerging companies; similarly only one deal involved two established companies; five deals were between established and start-up companies and four were between start-up companies and academic organisations. No global companies were involved in drug delivery deals in September. The types of deal varied considerably, as did the interest areas, ranging from anticancer and genitourinary products to surgical and medical devices. Two organisations were each involved in two deals during September: the National Cancer Institute (NCI, of the US NIH) and Cardinal Health. Read more... |
||
|
|
||
Featured Article21st-Century Electronics for 21st-Century Drugs: Electronic Stability Monitoring TechnologyMost 20th-century drugs were small molecules, well-preserved in a dry tablet form. These drugs generally had good stability, and were relatively tolerant to normal fluctuations in temperature during storage. However, in the 21st century we are seeing an increasing number of biotechnology drugs composed of large molecules, such as proteins, which are very sensitive to temperature extremes. We are also seeing an increasing number of advanced drug delivery devices, which often function using drugs that are stored in the form of liquids, hydrogels or lipid suspensions. Therefore, 21st-century drugs, although medically superior, are tending to have lower stability. In this article, Stephen E Zweig, CEO of CliniSense, explores the ways in which modern electronics, namely stability tags, can maximise the effectiveness of modern pharmaceutical technology. Read more... |
 |
||
|
|
||
 |
Company ProfilesActivaero, APR, Controlled Therapeutics, Lyfjathroun |
||
|
|
||
Drug Delivery OpportunitiesView all our Drug Delivery Opportunities or alternatively request a password to submit your opportunity online.Featured Opportunity Nanoemulsion Technology Administrative Route - Topical, Transdermal, Intranasal Indication - Lipophilic and hydrophilic compounds, bioactive agents, dermatological products, cosmeceuticals, herbal Licence code - LO-0609-03 |
 |
||
|
|
||
 |
Ensure you receive your copy of the Drug Delivery Report Autumn / Winter 2006For deal makers actively assessing drug delivery technology receiving your complimentary copy is a must. The DDR blends high-quality articles covering the latest drug developments in conjunction with concise profiles of companies active in specific technology areas.Apply to receive the next edition of the DDR Find out more about promoting your company |
||
Comprising two specialist areas - PharmaVentures Consulting and PharmaVentures Intelligence - we work with clients to drive greater value from their deals.
If you do not wish to receive DDR E-News in future, please e-mail ddr@pharmamail.biz with the words UNSUBSCRIBE as the subject.
If you do not wish to receive other e-mail communications from PharmaVentures or selected third parties, please e-mail ddr@pharmamail.biz with REMOVE as the subject.
For more details contact
Kate Atherton, Publishing Editor, PharmaVentures Ltd, Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK. Tel: +44 (0) 1865 784 177 Fax: +44 (0) 1865 784 178 E-mail ddr@pharmamail.biz